Technology for Accurate Care
New Technology for Prostate Cancer Diagnosis
KAPS Biotech's studies have shown that the known drawbacks of the currently available PSA test can be overcome by our panel of biomarkers. We have shown this panel of biomarkers can (better than PSA alone) differentiate benign prostate and PCa with greater specificity and identify men who have high risk (aggressive) PCa.
In published research (Clinical Cancer Investigation Journal 3:72-79, 2014), we have shown that concurrent measurements of IL-8, TNF-a, and soluble receptor for TNF-a (sTNFR1) can differentiate benign prostate and PCa with greater specificity than the PSA test alone. These biomarkers can also identify patients who have aggressive PCa.
Clinical Cancer Investigation Journal
Publication of the Middle-Eastern Association for Cancer Research
Prostate-specific antigen (PSA) is currently used as a biomarker for diagnosis and management of prostate cancer (CaP).
However, PSA typically lacks the sensitivity and specificity desired of a diagnostic marker. Objective: The goal of this study was to
identify an additional biomarker or a panel of biomarkers that is more sensitive and specific than PSA in differentiating benign
versus malignant prostate disease and/or localized CaP versus ....
To Download Full Study Submit Contact Info Below.